JPWO2023023070A5 - - Google Patents
Info
- Publication number
- JPWO2023023070A5 JPWO2023023070A5 JP2024510252A JP2024510252A JPWO2023023070A5 JP WO2023023070 A5 JPWO2023023070 A5 JP WO2023023070A5 JP 2024510252 A JP2024510252 A JP 2024510252A JP 2024510252 A JP2024510252 A JP 2024510252A JP WO2023023070 A5 JPWO2023023070 A5 JP WO2023023070A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- seq
- combination
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163233966P | 2021-08-17 | 2021-08-17 | |
| US63/233,966 | 2021-08-17 | ||
| PCT/US2022/040485 WO2023023070A2 (en) | 2021-08-17 | 2022-08-16 | Inducible il-2 and pd-1/pd-l1 combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024534080A JP2024534080A (ja) | 2024-09-18 |
| JP2024534080A5 JP2024534080A5 (https=) | 2025-08-25 |
| JPWO2023023070A5 true JPWO2023023070A5 (https=) | 2025-08-25 |
Family
ID=85239704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024510252A Pending JP2024534080A (ja) | 2021-08-17 | 2022-08-16 | 誘導性ｉｌ－２及びｐｄ－１／ｐｄ－ｌ１の併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240216470A1 (https=) |
| EP (1) | EP4387650A4 (https=) |
| JP (1) | JP2024534080A (https=) |
| KR (1) | KR20240051178A (https=) |
| CN (1) | CN118103058A (https=) |
| AU (1) | AU2022331262A1 (https=) |
| CA (1) | CA3229021A1 (https=) |
| WO (1) | WO2023023070A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3854805A4 (en) | 2018-09-21 | 2022-08-24 | Innovent Biologics (Suzhou) Co., Ltd. | NOVEL INTERLEUKIN 2 AND ITS USE |
| WO2025140535A1 (zh) * | 2023-12-28 | 2025-07-03 | 福佑泰生物制药（新加坡）公司 | Pd-1/il-2r双特异性抗体融合蛋白及其用途和使用方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6720075B2 (ja) * | 2013-05-31 | 2020-07-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 癌のための併用療法 |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| BR112022009110A2 (pt) * | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
-
2022
- 2022-08-16 CA CA3229021A patent/CA3229021A1/en active Pending
- 2022-08-16 KR KR1020247008939A patent/KR20240051178A/ko active Pending
- 2022-08-16 JP JP2024510252A patent/JP2024534080A/ja active Pending
- 2022-08-16 AU AU2022331262A patent/AU2022331262A1/en active Pending
- 2022-08-16 WO PCT/US2022/040485 patent/WO2023023070A2/en not_active Ceased
- 2022-08-16 EP EP22859050.1A patent/EP4387650A4/en active Pending
- 2022-08-16 CN CN202280069956.XA patent/CN118103058A/zh active Pending
-
2024
- 2024-02-13 US US18/440,775 patent/US20240216470A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018518454A5 (https=) | ||
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| JPWO2019189780A5 (https=) | ||
| Isambert et al. | Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors | |
| JP7797875B2 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| BR122023025321A2 (pt) | Uso de anticorpos anti-b7-h1 e anti-ctla-4 | |
| JP2021523170A5 (https=) | ||
| Akinleye et al. | Novel agents for advanced pancreatic cancer | |
| Barmettler et al. | Efficacy of cetuximab in combination with FOLFIRI in a patient with KRAS wild-type metastatic anal cancer | |
| CN119630421A (zh) | 用于治疗癌症的抗pd-1活性剂、抗tim-3活性剂和抗lag-3活性剂的组合疗法 | |
| JP2016524611A5 (https=) | ||
| US20080008704A1 (en) | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies | |
| Camera et al. | MOMENTUM: a phase I trial investigating 2 schedules of capecitabine with aflibercept in patients with gastrointestinal and breast cancer | |
| JPWO2023023070A5 (https=) | ||
| CN112915203B (zh) | 喹啉衍生物与pd-1单抗的药物组合 | |
| WO2021182570A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| WO2022103905A1 (en) | Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors | |
| TW202527995A (zh) | 抗b7h3抗體藥物偶聯物在製備治療鼻咽癌和/或肺淋巴上皮瘤樣癌的藥物中的用途 | |
| JP2018520990A (ja) | 抗ｆｇｆｒ４抗体および胆汁酸捕捉剤の組み合わせ | |
| Yoshida et al. | Early start of chemotherapy after resection of brain metastasis from colon cancer with synchronous multiple liver metastases | |
| JP7793985B2 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| JP7064544B2 (ja) | 癌の治療のための抗ｖｅｇｆｒ－２抗体と抗ｐｄ－ｌ１抗体との組み合わせ | |
| WO2022042537A1 (zh) | TGF-β受体的融合蛋白与多靶点酪氨酸激酶抑制剂联合在制备抗肿瘤药物中的用途 | |
| WO2024137442A1 (en) | Combination therapy for treating cancer | |
| Szklener et al. | Management of hepatocellular carcinoma with novel immunotherapeutic agents and prospects for the future |